Company intelligence / Profile preview

Bioeq AG

Ownership: Public · FYB
Employees: ~8
Development stage: Commercial

Overview

Bioeq is engaged in the licensing, development, and commercialization of biosimilar ranibizumab, a successor to the branded biopharmaceutical Lucentis

Therapeutic areas: Ophthalmology
Modalities: Biosimilars
Industry: Biotech

Drug pipeline

2 assets

ranibizumab

Commercial

Indications: Age-related macular degeneration, Choroidal neovascularization

1 more asset in the full pipeline.

Request access →

Partnerships

Polpharma Biologics GroupFormycon AG

Beyond the preview

Go deeper on Bioeq AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioeq AG.

Explore the full profile